DRTS
Alpha Tau Medical Ltd.
$9.85
+1.76%
$866.9M
No data for this timeframe.
Vol
Market Cap$866.9M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (82%)
Insider Activity0B / 1S
Insider Net $-$190.8K
Reddit Sentiment56° Neutral
SEC Reports1
Press Releases7
Exchange Nasdaq·Sector Surgical & Medical Instruments & Apparatus·Inc. L3·CIK 0001871321·Prev Close $9.68
Recent Activity
Jun 11, 2026
fda
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Earl
Jun 3, 2026
Press
Alpha Tau Medical announced a strategic collaboration with Tolmar Inc. for exclusive U.S. commercialization of Alpha DaR
Impact 7/10
Jun 3, 2026
Insider
Levy Raphi sold 17,500 shares
Chief Financial Officer @ $10.90 ($190.8K)
May 11, 2026
Press
Alpha Tau reported groundbreaking interim data from its REGAIN trial for recurrent glioblastoma, showing complete respon
Impact 7/10
Apr 27, 2026
SEC
Alpha Tau Medical announced abstract acceptance of pooled clinical data from 58 pancreatic cancer patients at the 2026 A
PRESS-RELEASE — Impact 6/10
Price Targets
$14.20
+44.2% upside
Strong Buy
Current $9.85
Low $8.00
Median $15.00
High $17.00
5 analysts
$8.00
$17.00
Analyst Ratings
4Strong Buy
5Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 4, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Jun 4, 2026 | Barclays | MAINTAIN | Overweight → Overweight |
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 28, 2026 | Barclays | INITIATE | Overweight |
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.14 ▼ -13.7% | $-0.15 — $-0.13 | -8% YoY | 4 |
| Next Q | $-0.14 ▼ -9.3% | $-0.14 — $-0.13 | 1% YoY | 4 |
| Current FY | $-0.66 ▼ -29.0% | $-0.69 — $-0.61 | -24% YoY | 5 |
| Next FY | $-0.51 ▼ -20.9% | $-0.58 — $-0.44 | 22% YoY | 5 |
Latest Reports
BULLISH
Press
7/10
Alpha Tau Medical announced a strategic collaboration with Tolmar Inc. for exclusive U.S. commercialization of Alpha DaR
Jun 3, 2026
MIXED
PRESS-RELEASE
6/10
Alpha Tau Medical announced abstract acceptance of pooled clinical data from 58 pancreatic cancer patients at the 2026 A
Apr 27, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Levy Raphi | SELL | $190.8K |
Reddit Sentiment
56°▼
Neutral
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
1 unique insiders with 1 transactions. Net insider value: -$190.8K ($0.00 bought, $190.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Levy Raphi | Chief Financial Officer | SELL | 17,500 | $10.90 | $190.8K |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.0/10.
BULLISH
7/10
Alpha Tau Medical announced a strategic collaboration with Tolmar Inc. for exclusive U.S. commercial
Jun 3, 2026
BULLISH
7/10
Alpha Tau reported groundbreaking interim data from its REGAIN trial for recurrent glioblastoma, sho
May 11, 2026
BULLISH
7/10
Alpha Tau completed enrollment in its ReSTART pivotal trial (88 patients) for Alpha DaRT in recurren
May 8, 2026
BULLISH
5/10
Alpha Tau Medical announced that an abstract on Alpha DaRT in combination with pembrolizumab for eld
May 5, 2026
BULLISH
7/10
Alpha Tau announced 100% local disease control in evaluable patients from pooled first-in-human tria
May 4, 2026
BULLISH
7/10
The FDA has approved an IDE supplement expanding Alpha Tau's IMPACT pilot trial for pancreatic cance
Apr 23, 2026
MIXED
6/10
Alpha Tau Medical reported its 2025 financial results, showing a wider net loss of $42.6 million ($0
Mar 9, 2026
Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 4 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$14.20 mean target
+44.2% upside
Strong Buy (1.60)
$8.00 Low
$17.00 High
| Metric | Value |
|---|---|
| Current Price | $9.85 |
| Target Low | $8.00 |
| Target Mean | $14.20 |
| Target Median | $15.00 |
| Target High | $17.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (1.60) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.14 | $-0.15 | $-0.13 | -8.4% | -13.7% | 1↑ 3↓ | $0.0B | 0.0% | 4 |
| Next Q 2026-09-30 |
$-0.14 | $-0.14 | $-0.13 | 1.2% | -9.3% | 1↑ 3↓ | $0.0B | 0.0% | 4 |
| Current FY 2026-12-31 |
$-0.66 | $-0.69 | $-0.61 | -24.3% | -29.0% | 0↑ 4↓ | $0.0B | 0.0% | 5 |
| Next FY 2027-12-31 |
$-0.51 | $-0.58 | $-0.44 | 21.8% | -20.9% | 0↑ 3↓ | $0.0B | 658.1% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.141 | |
| 7d ago | $-0.141 | |
| 30d ago | $-0.124 | -0.017 |
| 60d ago | $-0.124 | -0.017 |
| 90d ago | $-0.129 | -0.012 |
5 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 4, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jun 4, 2026 | Barclays | MAINTAIN | Overweight | Overweight |
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 28, 2026 | Barclays | INITIATE | — | Overweight |
| May 20, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 19, 2026 | Piper Sandler | MAINTAIN | Neutral | Neutral |
| May 12, 2026 | Ladenburg Thalmann | MAINTAIN | Buy | Buy |
| May 12, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 11, 2026 | Citigroup | MAINTAIN | Buy | Buy |
| Mar 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 4, 2026 | Piper Sandler | DOWNGRADE | Overweight | Neutral |
| Feb 24, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| Apr 1, 2026 | 4 | 4 | 2 | 0 | 0 | 80% | |
| Mar 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Feb 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
56°
Neutral
Bearish
Neutral
Bullish
32 mentions
11 bullish
7 bearish
29 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Jun 11, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 10, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| Jun 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Jun 4, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 27, 2026 | 2 | 58° Warm | 1 | 0 | 2 |
| May 27, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 21, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 18, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 18, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 13, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 12, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 12, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 11, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 11, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 9, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 9, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| May 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 6, 2026 | 1 | 50° Neutral | 0 | 0 | 1 |
| May 4, 2026 | 2 | 44° Neutral | 0 | 0 | 2 |
| May 4, 2026 | 2 | 44° Neutral | 0 | 0 | 2 |
| Apr 30, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 30, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Apr 30, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 18, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 25, 2026 | 1 | 40° Cool | 0 | 1 | 1 |
| Dec 30, 2025 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
SLS, ONDS, DRTS and HOVR
▲ 1
💬 1
⚡ 0.5
Thoughts on HOVR, SLS, DRTS and ONDS
▲ 1
💬 0
⚡ 0.5
Is DRTS a long-term hold?
▲ 1
💬 1
⚡ 0.5
Is DRTS a long-term hold?
▲ 1
💬 0
⚡ 0.5
Saving Millions and Making Millions, now more than ever
▲ 1
💬 0
⚡ 0.5
DRTS | Breakthrough In Glioblastoma Treatment
▲ 1
💬 0
⚡ 0.5
Follow up: Alpha Tau Medical DRTS (Huge win vs. rGBM)
▲ 1
💬 0
⚡ 0.5
Yall sleeping on DRTS and i dont get it
▲ 1
💬 1
⚡ 0.5
The secret OS numbers of DRTS in Pancreatic Cancer
▲ 1
💬 1
⚡ 0.5
DRTS: Alpha Tau is gonna save lives long term
▲ 1
💬 0
⚡ 0.4
Jun 11, 2026
fda
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Trial and Add Two U.S. Sites; Early Interim Results Showed 100% Local Disease Contro
Jun 4, 2026
short_volume
Short Volume: DRTS — 58.2% short (0.4M / 0.6M)
Short: 368,151 | Exempt: 2,122 | TRF Vol: 632,988 | Short Ratio: 58.2% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
contract
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
Jun 3, 2026
short_volume
Short Volume: DRTS — 59.7% short (0.7M / 1.2M)
Short: 743,145 | Exempt: 292 | TRF Vol: 1,244,894 | Short Ratio: 59.7% | Off-exchange volume (dark pool + OTC)
Jun 2, 2026
short_volume
Short Volume: DRTS — 61.8% short (0.4M / 0.6M)
Short: 356,686 | Exempt: 17,444 | TRF Vol: 577,507 | Short Ratio: 61.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: DRTS — 63.5% short (0.6M / 0.9M)
Short: 563,652 | Exempt: 41,330 | TRF Vol: 887,008 | Short Ratio: 63.5% | Off-exchange volume (dark pool + OTC)
May 25, 2026
earnings_calendar
DRTS Q1 2026 Earnings Scheduled — 2026-05-25
May 18, 2026
earnings
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
Alpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update
May 18, 2026
other
Alpha Tau to Participate in May Investor Conferences
Alpha Tau to Participate in May Investor Conferences 2026
May 12, 2026
short_interest
FTD: DRTS — 257,360 shares ($2.7M) failed to deliver
Settlement: 20260512, Price: $10.34, FTD Value: $2,661,102.4, ALPHA TAU MED LTD ORD SHS (ISR
May 11, 2026
fda
Alpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET
<p align="center"><em>- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total dis
May 11, 2026
short_volume
Short Volume: DRTS — 67.3% short (1.0M / 1.5M)
Short: 1,023,590 | Exempt: 9,338 | TRF Vol: 1,519,897 | Short Ratio: 67.3% | Off-exchange volume (dark pool + OTC)
May 8, 2026
routine
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
Alpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent Glioblastoma
May 8, 2026
fda
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma
Alpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to ReSTART
May 5, 2026
fda
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab
Alpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha D